MRC Centre for Medical Mycology, School of Biosciences, University of Exeter, Geoffrey Pope Building, Exeter, EX4 4QD, UK.
Medical Research Council, Polaris House, Swindon, SN2 1FL, UK.
Nat Commun. 2022 Sep 12;13(1):5352. doi: 10.1038/s41467-022-32249-5.
Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health care priority. Some analyses, including the O'Neill report, have predicted that deaths due to drug-resistant bacterial infections may eclipse the total number of cancer deaths by 2050. Although fungal infections remain in the shadow of public awareness, total attributable annual deaths are similar to, or exceeds, global mortalities due to malaria, tuberculosis or HIV. The impact of fungal infections has been exacerbated by the steady rise of antifungal drug resistant strains and species which reflects the widespread use of antifungals for prophylaxis and therapy, and in the case of azole resistance in Aspergillus, has been linked to the widespread agricultural use of antifungals. This review, based on a workshop hosted by the Medical Research Council and the University of Exeter, illuminates the problem of antifungal resistance and suggests how this growing threat might be mitigated.
在 SARS-CoV-2 大流行之前,抗生素耐药性已被列为主要的全球医疗保健重点。一些分析,包括奥尼尔报告,预测到 2050 年,死于耐药细菌感染的人数可能超过癌症死亡总数。尽管真菌感染仍然不为公众所了解,但总归因于每年的死亡人数与疟疾、结核病或艾滋病毒导致的全球死亡率相似,甚至超过了疟疾、结核病或艾滋病毒导致的全球死亡率。抗真菌药物耐药菌株和种类的稳步上升加剧了真菌感染的影响,这反映了抗真菌药物在预防和治疗中的广泛使用,而在曲霉菌唑耐药的情况下,与农业中广泛使用抗真菌药物有关。本综述基于医学研究理事会和埃克塞特大学主办的一次研讨会,阐明了抗真菌药物耐药性的问题,并提出了如何缓解这一日益严重的威胁。